J P Leonard
Overview
Explore the profile of J P Leonard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
2202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Goy A, Bernstein S, Kahl B, Djulbegovic B, Robertson M, de Vos S, et al.
Ann Oncol
. 2008 Dec;
20(3):520-5.
PMID: 19074748
Background: We previously reported results of the phase 2, multicenter PINNACLE study, which confirmed the substantial single-agent activity of bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL)....
12.
Yang C, Lu P, Lee F, Chadburn A, Barrientos J, Leonard J, et al.
Leukemia
. 2008 Jul;
22(9):1755-66.
PMID: 18596745
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Although some patients can be cured by current therapies, novel agents are needed to further improve outcomes....
13.
Leonard J, MARTIN P, Ruan J, Elstrom R, Barrientos J, Coleman M, et al.
Ann Oncol
. 2008 Jun;
19 Suppl 4:iv60-2.
PMID: 18519407
No abstract available.
14.
Elstrom R, Leonard J, Coleman M, Brown R
Ann Oncol
. 2008 Jun;
19(10):1770-3.
PMID: 18550578
Background: Positron emission tomography (PET) is more accurate than computed tomography (CT) in staging and restaging of lymphoma, but both are considered necessary. Increasingly, PET is carried out with a...
15.
MARTIN P, Chadburn A, Christos P, Furman R, Ruan J, Joyce M, et al.
Ann Oncol
. 2008 Mar;
19(7):1327-1330.
PMID: 18349031
Background: Reported median overall survival (OS) in patients with mantle cell lymphoma (MCL) has been reported to be just 3-4 years. As a consequence, first-line treatment has become more aggressive....
16.
Leonard J, Goldenberg D
Oncogene
. 2007 May;
26(25):3704-13.
PMID: 17530024
The vast majority of non-Hodgkin's lymphomas are of B-cell phenotype. Development of unlabeled or radiolabeled therapeutic monoclonal antibodies against the cell surface antigen, CD20, has revolutionized the treatment of these...
17.
Leonard J, Friedberg J, Younes A, Fisher D, Gordon L, Moore J, et al.
Ann Oncol
. 2007 May;
18(7):1216-23.
PMID: 17470451
Background: Galiximab is a monoclonal antibody that targets CD80, a costimulatory molecule constitutively expressed on follicular and other lymphomas. Modest single-agent clinical activity and tolerability were demonstrated in a phase...
18.
Navolanic P, Pui C, Larson R, Bishop M, Pearce T, Cairo M, et al.
Leukemia
. 2003 Mar;
17(3):499-514.
PMID: 12646938
Renal precipitation of uric acid associated with tumor lysis syndrome (TLS) is a major complication in the management of leukemia, lymphoma, and other drug-sensitive cancers. Management of hyperuricema has historically...
19.
Press O, Leonard J, Coiffier B, Levy R, Timmerman J
Hematology Am Soc Hematol Educ Program
. 2001 Nov;
:221-40.
PMID: 11722986
Recent years have witnessed the development of a variety of promising immunotherapies for treating patients with non-Hodgkin's lymphomas. Foremost among these advances is the exciting success of monoclonal antibodies directed...
20.
Leonard J, Schattner E, Coleman M
Curr Opin Oncol
. 2001 Sep;
13(5):342-7.
PMID: 11555710
Mantle cell lymphoma is a distinct subtype and accounts for approximately 5 to 10% of non-Hodgkin lymphomas. The malignant cells express pan B-cell markers, including CD19, CD20 and CD22, and...